Autoimmune Hepatitis
Conditions
Brief summary
The purpose of this study is to compare the pharmacokinetics of JKB-122 tablets with JKB-122 capsules in healthy male subjects subjects.
Detailed description
This clinical study will be a randomized, open-label, multiple-dose, two-period, crossover study in healthy male subjects. After screening, subjects will be randomized to receive either JKB-122 tablet or JKB-122 capsule in a 1:1 ratio. There will be two dosing periods (Period 1 and Period 2). Subjects who receive JKB-122 capsule during Period 1 will receive JKB-122 tablet during Period 2 and vice versa. The 2 dosing periods will be separated by a washout period.
Interventions
DRUGJKB-122 in capsule or tablet form
JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form
Sponsors
TaiwanJ Pharmaceuticals Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. The subject has a body mass index (BMI) range of 18.5 and \< 25.0 kg/m2 and weighs at least 50 kg. 2. Agreement for subject and female partner of childbearing potential to use acceptable method of contraception 3. The subject provided written informed consent.
Exclusion criteria
1. Any history or evidence of any clinically significant major disease or malignancy, as judged by the Investigator. 2. Any clinically significant abnormality following the Investigator's review of the physical examination, ECG and clinical study protocol-defined clinical laboratory tests. 3. Use of prescribed or non-prescribed drugs (including vitamins, natural and herbal remedies, e.g. St. John's Wort) in the 2 weeks prior to study drug administration. 4. Consumption of grapefruit, pomelo, citrus fruits, starfruit, pomegranate, papaya, mango, rambutan, kiwi fruit, dragon fruit or passion fruit and products containing these fruits in the 2 weeks prior to study drug administration. 5. Current smoker or history of smoking within 3 months before the Screening Visit. 6. History of drinking more than 21 units of alcohol per week within 3 months prior to the Screening Visit. 7. Any use of drugs-of-abuse within 3 months before the Screening Visit. 8. Any significant blood loss or donation of blood (250 ml within 2 months or 500 ml within 3 months) prior to study drug administration. 9. Positive serology test for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (HCVAb) or human immunodeficiency virus. 10. Participation in any clinical study or administration of any investigational product within 1 month of study drug administration. 11. The subject has any other condition, which in the opinion of the Investigator precludes the subject's participation in the clinical study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area under the curve from the time of dosing to steady state (AUC¬(0-τ)ss¬¬) | 2 WEEKS | Plasma PK parameters will be measured comparison between JKB-122 capsule and JKB-122 tablet |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse events (AEs) observed | 2 WEEKS | Safety observation of the drug treatment. |
Contacts
Primary ContactYing-Chu Shih, PhD
Outcome results
None listed